<DOC>
	<DOC>NCT01120327</DOC>
	<brief_summary>1. OBJECTIVES Primary objective to evaluate the difference of the peak oxygen uptake change (VO2 max, mL/kg/min) in amlodipine group against no CCB group at 9 months Secondary objectives To evaluate the change of sublingual nitrate use per day against no CCB group at 1 and 3 months To evaluate the change of biomarkers against no CCB group at 9 months 2. SUBJECTS AND CENTERS 212, stable angina patients with angiographically confirmed significant residual stenosis 10, 3rd-grade, teaching hospitals in Korea</brief_summary>
	<brief_title>A Pilot Study Exploring Efficacy and Safety of Amlodipine in the Stented Angina Patients</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Stable angina patient with angiographically confirmed significant residual stenosis Stenosis more than 50% in 2 major coronary arteries at least or Stenosis more than 75% in 1 major coronary artery No other pulmonary/psychiatry/musculoskeletal disorder limiting CPET Contraindicated to the CPET (e.g. unstable angina, aortic stenosis, uncontrolled hypertension, uncontrolled asthma, hypoxemia at rest, epilepsy, locomotor disorder, severe hypertension and febrile illness)</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2010</verification_date>
</DOC>